Association of nesfatin-1 levels with fasting and postload glucose levels in patients with hypothyroidism

Serap Baydur ŞAHİN, Teslime AYAZ, Medine CUMHUR CÜRE, Fatih SUMER, Kadir İLKKILIÇ
1.636 359

Abstract


Nesfatin-1, which is known as an anorexigenic peptide, has a potential role in the control of glucose/insulin regulation. We aimed to investigate serum nesfatin-1 levels in patients with untreated hypothyroidism due to Hashimoto’s thyroiditis and correlate with fasting plasma glucose (FPG) and postload glucose levels. This study included 40 patients with hypothyroidism (mean age; 32.3±12.6 years, body mass index (BMI); 27.8±7.9 kg/m2) and 54 age and BMI matched healthy control group (mean age; 29.3±8.5 years BMI; 29.7±7kg/m2). All subjects underwent a 75 gr oral glucose tolerance test. Serum nesfatin 1 levels were similar among the hypothyroid subjects and control group (14.1±13.4 vs 16.7±15.4 ng/ml, respectively) (p=0.152). FPG (95±8 vs 96.6±7.9 mg/dl) and 2 h postload glucose (113.6±26.7 vs 113.1±27.5 mg/dL) levels did not differ between the two groups (p=0.339, p=0.976 (respectively)). There was no significant correlation between nesfatin-1 and free T3, free T4, TSH, anti-thyroglobulin autoantibody (TGAb) and antithyroid peroxidase autoantibody (TPOAb) (p>0.05). While nesfatin 1 levels did not correlate with FPG, 2 h postload glucose, The Homeostasis Model Assessment (HOMAIR), total-cholesterol, HDL-cholesterol and LDL-cholesterol levels, it showed a negative correlation with triglyceride levels (p=0.008). Nesfatin-1 levels were not associated with FPG and postload glucose levels in patients with hypothyroidism.


Keywords


Glucose; homeostasis model assessment insulin; resistance index; hypothyroidism; nesfatin-1; triglyceride

Full Text:

217-220


References


Abaci, A., Catli, G., Anik, A., Kume, T., Bober, E., 2013. The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr. Diabetes. 14, 189-195. doi:10.1111/pedi.12009.

Altinova, A.E., Toruner, F., Karakoc, A., Yetkin, I., Ayvaz, G., Cakir, N., Arslan, M., 2006. Serum ghrelin levels in patients with hashimoto’s thyroiditis. Thyroid. 16, 1259-1264. doi:10.1089/thy.2006.16.1259.

Başar, O., Akbal, E., Köklü, S., Koçak, E., Tuna, Y., Ekiz, F., Gültuna, S., Yιlmaz, F.M., Aydoğan, T., 2012. A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand. J. Clin. Lab. Invest. 72, 479-483. doi:10.3109/00365513.2012.699097.

Foo, K.S., Brauner, H., Ostenson, C.G., Broberger, C., 2010. Nucleobindin-2/nesfatin in the endocrine pancreas: Distribution and relationship to glycaemic state. J. Endocrinol. 204, 255-263. doi:10.1677/JOE-09-0254.

Gokcel, A., Ozsahin, A.K., Sezgin, N., Karakose, H., Ertorer, M.E., Akbaba, M., Baklaci, N., Sengul, A., Guvener, N., 2003. High prevalence of diabetes in Adana, a southern province of Turkey. Diabetes Care. 26, 3031-3034. doi:10.2337/diacare.26.11.3031

Gonzalez, R., Reingold, B.K., Gao, X., Gaidhu, M.P., Tsushima, R.G., Unniappan, S., 2011. Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet β- and MIN6 cells. J. Endocrinol. 208, 9-11. doi:10.1530/JOE-10-0492.

Iglesias, P., Díez, J.J., 2007. Influence of thyroid dysfunction on serum concentrations of adipocytokines. Cytokine. 40, 61-70. doi:10.1016/j. cyto.2007.10.001.

Li, Q.C., Wang, H.Y., Chen, X., Guan, H.Z., Jiang, Z.Y., 2010. Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul. Pept. 159, 72-77. doi:10.1016/j.regpep.

Li, Z., Gao, L., Tang, H., Yin, Y., Xiang, X., Li, Y., Zhao, J., Mulholland, M., Zhang, W., 2013. Peripheral effects of nesfatin-1 on glucose homeostasis. PLoS One. 8, e71513. doi: 10.1371/journal.pone.0071513.

Nakata, M., Manaka, K., Yamamoto, S., Mori, M., Yada, T., 2011. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet β-cells. Endocr. J. 58, 305-313. doi:10.1507/endocrj.K11E-056.

Oh-I, S., Shimizu, H., Satoh, T., Okada, S., Adachi, S., Inoue, K., Eguchi, H., Yamamoto, M., Imaki, T., Hashimoto, K., Tsuchiya, T., Monden, T., Horiguchi, K., Yamada, M., Mori, M., 2006. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 443, 709-712. doi:10.1038/nature05162.

Pucci, E., Chiovato, L., Pinchera, A., 2000. Thyroid and lipid metabolism. Int. J. Obes. Relat. Metab. Disord. 24, 109-112.

Sawicka, B., Bossowski, A., Urban, M., Szalecki, M., Wysocka, J., Koput, A., Zelazowska-Rutkowska, B., Tobolczyk, J., Skrzydło, M., Rogowski, F., Luba, M., 2009. Analysis of serum levels of ghrelin and obestatin in children and adolescents with autoimmune thyroid diseases. Pediatr. Endocrinol. Diabetes Metab. 15, 20-27.

Sawicka, B., Bossowski, A., 2013. Analysis of serum levels of nesfatin-1 in children and adolescents with autoimmune thyroid diseases. Pediatr. Endocrinol. Diabetes Metab. 19, 5-10.

Shimizu, H., Oh-I, S., Okada, S., Mori, M., 2009. Nesfatin-1: An overview and future clinical application. Endocr. J. 56, 537-543. doi: 10.1507/ endocrj.K09E-117.

Stengel, A., Taché, Y., 2011. Minireview: Nesfatin-1 an emerging new player in the brain-gut, endocrine, and metabolic axis. Endocrinology. 152, 4033-4038. doi:10.1210/en.2011-1500.

Su, Y., Zhang, J., Tang, Y., Bi, F., Liu, J.N., 2010. The novel function of nesfatin-1: Anti-hyperglycemia. Biochem. Biophys. Res. Commun. 391, 1039-1042. doi:10.1016/ j.bbrc.2009.12.014.

World Health Organization: definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of a WHO/IDF Consultation. Geneva., 2006. World Health Org.

Zhang, Z., Li, L., Yang, M., Liu, H., Boden, G., Yang, G., 2012. Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. 120, 91-95. doi:10.1055/s-0031-1286339.